Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma

Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma

A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a synergistic cytotoxic ratio. Both the molecules hav...

Descrizione completa

Dettagli Bibliografici
Autori principali: Yige Fu, Aishwarya Saraswat, Zenghui Wei, Manas Yogendra Agrawal, Vikas V. Dukhande, Sandra E. Reznik, Ketan Patel
Natura: Articolo
Lingua:English
Pubblicazione: MDPI AG 2021-07-01
Serie:Pharmaceutics
Soggetti:
ARV-825
proteolysis targeting chimera
nintedanib
vemurafenib-resistant melanoma
PEGylated nanoliposomes
synergistic interaction
Accesso online:https://www.mdpi.com/1999-4923/13/7/1005

Accesso online

https://www.mdpi.com/1999-4923/13/7/1005

Documenti analoghi